Reduced TGFβ1 activity is a common feature in the development of prolactinoma, studies also found that the recovery of TGFβ1 activity emerges as a novel therapeutic target for the treatment of DA-resistant patients (6). This evidence concerns the gene TGFB1 and prolactin-producing pituitary gland adenoma.